Chronic myeloid leukemia is a c10nal disorder of primitive hematopoietic stem cells characterized by leukocytosis splenomegaly, with a drift of progression in accelerated and blastic chronic phases and also due to the presence of Philadelphia chromosome. Theaverage age of patients at presentation fluctuates between 45to 55 years, while 12 to 30% of patients are 60 years of age or older, an important consideration for therapeutic strategies. Most of the patients (85%) show up in the chronic phase; about 40 to 50% of the cases are diagnosed by routine tests. Common findings at presentation are fatigue, weight loss, abdomínalfullness. The BCR-ABL protein plays a central roll in Chronic Myeloid Leukemia physiopathology. Imatinib Mesylate, is the first successful medicament developed to inhibit the BCR-ABL protein tyrosine kinase activity, changing the paradigms of therapeutics approaches in this disease.
Downloads
Download data is not yet available.
References
Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian H. The Biology of Chronic Myeloid Leukemia. N Engl J Med 1999;341:164.
Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960;132:1497.
Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia. Nature 1973;243:290-3.
Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the p210 gene of the Philadelphia chromosome. Science 1990;247:824.
Melo JV. The diversity of bcr-abl fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-84.
Deininger MW, Goldman J, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96(10):3343-56.
Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 1993;11(suppl1):11-5.
Kantarjian H, Keating M, Talpaz M. Chronic myeloid leukemia in blast crisis: analysis of 242 patients. Am J Med 1987;83:445-54.
Stuppia L, Calabrese G, Peila R. P53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blast crisis. Cancer Genet Cytogenet 1997;98:28-35.
Litz CE, Vos JA, Copenhaver CM. Aberrant methylation of the major break cluster region in chronic myeloid leukemia. Blood 1996;88:2241-9.
Hehlmann R, Heimpel H, Hasford J. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993;82:398-407.
Clift R, Buckner CD, Thomas ED. Treatment of chronic granulocytic leukemia in chronic phase by allogeneic marrow transplantation. Lancet 1982;2:621-3.
Horowitz M, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17(suppl 3):S5-S6.
Clift R, Anasetti C. Allografting for chronic myeloid leukemia. Baillieres Clinical Hematology 1997;10:319-36.
Horowitz M, et al. Graft versus leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
Talpaz M, Silver RT, Druker BJ. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study. Blood 2002;99:1928-37.
Druker B, Talpaz M, Resta D. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-37.
Sokal JE, Cox EB, Baccarani M. Prognostic discrimination "good risk" chronic granulocytic leukemia. Blood 1984;63:789.
O'Brien S, Guilhot F, Larson RA. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
